Journal of Ophthalmology / 2012 / Article / Tab 2

Clinical Study

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

Table 2

Recurrence rates of exudative changes after successful initial treatment.

Initial treatmentEyes (%)Recurrence eyes (%)

1 PDT + 2 ranibizumab23 (60.5%)1 (4.3%)
1 PDT + 3 ranibizumab9 (23.7%)2 (22.2%)
1 PDT + 4 ranibizumab2 (5.3%)1 (50.0%)
1 PDT + 5 ranibizumab2 (5.3%)0 (0.0%)
2 PDT + 6 ranibizumab2 (5.3%)0 (0.0%)

Total38 eyes4 eyes (10.5%)

PDT: photodynamic therapy.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.